| Li Zheng,Min Zhao,Xiangyang Hu,Jin Huang,Ling Ang,Hongguang Hu,Qiang Zou,Jin Wang,Mingqiang Liu,Yang Zhao. Clinical significance of HBME-1, Galectin-3, and CK19 expression and the status of BRAF mutation in papillary thyroid carcinoma. Oncol Transl Med, 2016, 2: 174-178. |
| Galectin-3、CK19、HBME-1表达和BRAF突变在甲状腺乳头状癌中的意义 |
| Clinical significance of HBME-1, Galectin-3, and CK19 expression and the status of BRAF mutation in papillary thyroid carcinoma |
| Received:February 13, 2016 Revised:July 23, 2016 |
| DOI：10.1007/s10330-016-0145-9 |
| 中文关键词: 甲状腺乳头状癌; Galectin-3; CK19; HBME-1 ; BRAF |
| 英文关键词: papillary thyroid carcinoma (PTC); human bone marrow endothelial cell markers (HBME-1); Galectin-3; cytokeratin19 (CK19); v-raf murine sarcoma viral oncogene homolog B1 (BRAF) |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Li Zheng | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Min Zhao* | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | Zhao.Min.hi@163.com | | Xiangyang Hu | Department of Pathology, Anhui Medical University, Hefei 230032, China | zhengli352@163.com | | Jin Huang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Ling Ang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Hongguang Hu | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Qiang Zou | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Jin Wang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Mingqiang Liu | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Yang Zhao | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com |
|
| Hits: 9425 |
| Download times: 10842 |
| 中文摘要: |
| 摘要 目的 探讨半乳糖凝集素3（Galectin-3）、细胞角蛋白19（CK19）、人骨髓内皮细胞标记物（HBME-1）蛋白表达和鼠类肉瘤滤过性毒菌致癌同源体B1（BRAF）基因突变在甲状腺乳头状癌（PTC）中的意义 方法 采用免疫组化Envision法检测82例PTC和82例甲状腺良性病变中Galectin-3、CK19、HBME-1蛋白表达状况; 采用聚合酶链反应及DNA测序法检测60例PTC和60例甲状腺良性病变中BRAF基因突变状况。结果 ① 82例PTC中HBME-1 、Galectin-3和CK19的阳性表达率分别为98.8%、97.6%、100%，与良性病变比较，差异有统计学意义（P＜0.05），而与临床病理参数间无相关性；另外联合检测3项蛋白指标，并以HBME-1联合 CK19或Galectin-3同时表达作为PTC诊断标准时，敏感度可高达99.9%，特异度达95.4% ；② 60例PTC中BRAF基因突变率为66.7%，与良性病变比较，差异有统计学意义（P＜0.05），与临床病理参数间无相关性。结论 ① 蛋白标记物Galectin-3、CK19、HBME-1对PTC的诊断均有一定病理价值，其中以HBME-1最为理想，联合检测特异度敏感性更佳；② BRAF基因突变是PTC发生的一项重要事件，对其确诊可能具有价值。 |
| 英文摘要: |
| Objective: The aim of this study was to explore the clinical significance of the expression of proteins
human bone marrow endothelial cell markers (HBME-1), Galectin-3, and cytokeratin19 (CK19), as well
as the status of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation in papillary thyroid
carcinoma (PTC).
Methods: Immunohistochemical staining was performed in 82 specimens each of PTC and papillary benign
lesions to detect the expression of HBME-1, Galectin-3, and CK19. Polymerase chain reaction (PCR)
and gene sequencing were performed on 60 specimens each of PTC and papillary benign lesions to detect
the status of BRAF mutation.
Results: The positive expression ratios of HBME-1, Galectin-3, and CK19 in PTC were 98.8%, 97.6%
and 100% respectively, which were significantly higher than the expressions in papillary benign lesions
(P < 0.05). No significant relationship was observed between the expression of these makers and the
clinicopathological features of PTC. The sensitivity of co-expression of HBME-1 and CK19 or HBME-1 and
Galectin-3 as diagnostic criteria of PTC was 99.9%, with a specificity of 95.4%. BRAF mutation was detected
in 40 of 60 PTC (66.7%) specimens. There was a statistical difference in BRAF mutations between
PTC and papillary benign lesions (P < 0.05); there were no associations between BRAF mutation and the
clinicopathological features of PTC.
Conclusion: Combined immunohistochemical staining of HBME-1, Galectin-3, and CK19 can further improve
the sensitivity and specificity of differential diagnosis of PTC. BRAF mutation is a significant genetic
event, which may have diagnostic value for PTC. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|